Common Superbugs

Superbugs are not a specific type of bacteria. All bacterial species can become superbugs. But in order to prevent superbug infections and the development of therapeutic drugs in priority areas, knowing the common superbugs to watch out for can be helpful.

The World Health Organization (WHO) has identified 12 families of bacteria that are most in need of new antibiotic treatments. They are divided into three categories: critical, high and moderate. These 12 bacteria are prioritized based on the level of resistance already present in each. The issue is critical as antibiotic-resistant superbugs become more common.

Critical pathogens are those that cause serious infections and high mortality rates. Three bacteria are listed as critical: Acinetobacter Baumannii, Pseudomonas Aeruginosa, and Enterobacterales.

Acinetobacter Baumannii

Pseudomonas Aeruginosa

Enterobacterales

Critical Bacteria

Learn about their antibiotic resistance and infections

Acinetobacter Baumannii

Acinetobacter baumannii is resistant to carbapenem antibiotics. It is a highly drug-resistant bacterium that can cause a range of infections in patients, including pneumonia, wound or bloodstream infections.

Pseudomonas Aeruginosa

Pseudomonas Aeruginosa is resistant to carbapenem antibiotics. This resistant bacterium may cause rashes and ear infections in healthy individuals, as well as serious bloodstream infections and pneumonia in hospital patients.

Enterobacterales

Enterobacterales is resistant to both carbapenems and cephalosporins antibiotics. It is a bacterium that lives in the human intestine.

High Priority Bacteria

Enterococcus faecium

Enterococci have developed a variety of mechanisms of resistance to several antibiotics like aminoglycosides, B-lactams, tetracyclines, quinolones, and vancomycin (glycopeptide).

Staphylococcus aureus

S. aureus strains are resistant to the isoxazoyl penicillins such as methicillin, oxacillin and flucloxacillin and resistant to vancomycin-intermediate.

Helicobacter pylori

Helicobacter pylori infections have been treated using the macrolide antibiotic, clarithromycin. Clarithromycin resistance is increasing worldwide and is the most common cause of H. pylori treatment failure.

Campylobacter spp.

Campylobacter remain a leading cause of bacterial gastroenteritis worldwide. Fluoroquinolones are among the most common treatments. Selection pressure in the presence of fluoroquinolones rapidly leads to resistance in Campylobacter.

Salmonellae

Salmonella is co-resistance to the first-line antibiotics ampicillin, chloramphenicol and trimethoprim/sulfamethoxazole. Resistance of Salmonella to fluoroquinolone has been increasingly reported after the introduction of fluoroquinolone drug therapy.

Neisseria gonorrhoeae

Antibiotic resistance in Neisseria gonorrhoeae is rapidly increasing. Extensively resistant Neisseria gonorrhoeae is resistant to both penicillins, sulfonamides, tetracyclines, fluoroquinolones, and macrolides.

These bacteria, classified as high priority, may cause significant infections in other healthy populations. These six bacterial families are a high threat to our health care. This is because their antibiotic resistance is growing, and we have nearly exhausted our treatment options.

Urgent antibiotic needs --- We are seeking new weapons to fight superbugs

Research on antibiotic resistance is important, and it is one of the biggest threats to modern health. Therefore, the development of new treatments for superbugs will be a long-term endeavor. We urgently need new antibiotics to be developed in a timely manner.

Contact Us

We are a biotechnology company that specializes in the research and development of new treatments for superbugs. Don't put us at risk for superbug infections and difficult treatments - feel free to contact us for research help. We will help and make sure your research project goes smoothly.

All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.